Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50881-0028-01 50881-0028 Pemigatinib PEMAZYRE 13.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
50881-0027-01 50881-0027 Pemigatinib PEMAZYRE 9.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral Apr 17, 2020 In Use
64842-0120-04 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb 3, 2023 In Use
72730-0101-01 72730-0101 infigratinib TRUSELTIQ 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
64842-0120-06 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb 3, 2023 In Use
72730-0202-01 72730-0202 infigratinib TRUSELTIQ 75.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
64842-0128-08 64842-0128 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Jun 1, 2026 In Use
64842-0127-07 64842-0127 FUTIBATINIB LYTGOBI 16.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Jun 1, 2026 In Use
64842-0120-05 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb 3, 2023 In Use
72730-0111-01 72730-0111 infigratinib TRUSELTIQ 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0506-01 72730-0506 infigratinib TRUSELTIQ 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72607-0100-00 72607-0100 tazemetostat TAZVERIK 200.0 mg/1 Chemotherapy Enzyme Inhibitor EZH2 Oral Jan 23, 2020 Apr 30, 2029 In Use
00002-1717-28 00002-1717 Imlunestrant Inluriyo 200.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ER⍺ Oral Oct 16, 2025 In Use
00002-1717-56 00002-1717 Imlunestrant Inluriyo 200.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ER⍺ Oral Oct 15, 2025 In Use
00002-1717-61 00002-1717 Imlunestrant Inluriyo 200.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ER⍺ Oral Nov 13, 2025 In Use
72187-0102-03 72187-0102 Elacestrant ORSERDU 345.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ERα Oral Jan 27, 2023 In Use
72187-0101-03 72187-0101 Elacestrant ORSERDU 86.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ERα Oral Jan 27, 2023 In Use
00310-0075-95 00310-0075 Camizestrant ETCAMAH 75.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ERα Oral Sep 4, 2026 In Use
00310-0075-01 00310-0075 Camizestrant ETCAMAH 75.0 mg/1 Hormonal Therapy Estrogen Receptor Antagonist ERα Oral Sep 4, 2026 In Use
84043-0200-30 84043-0200 Vepdegestrant VEPPANU 200.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, cereblon/CRBN Oral May 1, 2026 In Use
71332-0008-30 71332-0008 Vepdegestrant VEPPANU 200.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Oral Jun 16, 2026 In Use
71332-0007-30 71332-0007 Vepdegestrant VEPPANU 100.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Oral Jun 16, 2026 In Use
84043-0100-30 84043-0100 Vepdegestrant VEPPANU 100.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Oral May 1, 2026 In Use
00015-1911-13 00015-1911 Ixabepilone Ixempra Chemotherapy Antitumor Antibiotic Epothilones Intravenous Oct 16, 2007 Oct 31, 2017 No Longer Used
00015-1910-12 00015-1910 Ixabepilone Ixempra Chemotherapy Antitumor Antibiotic Epothilones Intravenous Oct 16, 2007 Oct 31, 2017 No Longer Used

Found 12611 results — Export these results